09:48 AM EST - Theralase Technologies Inc. : Has successfully completed the toxicology analysis of its lead Photo Dynamic Compound, TLD-1433, in compliance with Good Laboratory Practice standards. This milestone is critical for a Clinical Trial Application submission to Health Canada. Theralase Technologies Inc.
shares V.TLT are trading unchanged at $0.30.
